Recombinant Human PCSK9 Protein (C-His)

Measured by functional ELISA. Immobilized recombinant human PCSK9 binds recombinant human LDLR and reference anti-PCSK9 antibody (evolocumab/alirocumab class) with EC50 values in the ng/mL range.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a secreted serine protease that has become the second most important lever on LDL cholesterol after statins. Secreted by the liver, PCSK9 binds the LDL receptor on hepatocytes and escorts it to lysosomal degradation; blocking this interaction with the antibodies evolocumab and alirocumab, or silencing PCSK9 with inclisiran, dramatically lowers LDL-C and cardiovascular risk. The secreted protein is processed from a zymogen into a prodomain plus mature catalytic form that remains non-covalently associated — both parts participating in receptor binding. Recombinant human PCSK9 is the standard reagent for PCSK9–LDLR competition assays, antibody screening and lipid-metabolism research.